As treatment for RA, 60.27% of patients received GCs, 45.53% were treated with csDMARDs, 5.51% were prescribed JAKis, 14.6% received TNF-α inhibitors, 2.68% were administered IL-6 inhibitors, 2.25% received RTX, and 2.92% were treated with ABA. Here, TNF is linked to rheumatoid arthritis.